Miguel Cervero Jiménez-rekin lankidetzan egindako argitalpenak (8)

2024

  1. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

2023

  1. Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study—The U-SEX-2 GESIDA 9416 Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2021

  1. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  2. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

    Biochemical Pharmacology, Vol. 192

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118